Updates with comments from UBS note
** Cochlear COH.AX slides as much as 14.1% to A$261.73; set for worst day since March 2020
** Stock at lowest level since November 2023
** Hearing implants maker reports HY underlying NPAT of A$206 mln ($206 mln), missing Visible Alpha consensus of A$209.3 mln
** Expects FY underlying net profit to be at lower end of A$410 mln-A$430 mln forecast range
** UBS says, "New expectations for being at lower end of profit guidance could cause concern or it could just be a blip if services revenue in fiscal 2026 can pick up again with new product launches"
** Expects single-digit decline in FY services revenue
** COH among worst performers on ASX 200 benchmark index .AXJO
** Stock, one of the priciest in the country, down ~9% YTD
($1 = $1.0000)
(Reporting by Himanshi Akhand and Roshan Thomas in Bengaluru)
((Himanshi.Akhand@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.